Pozen, CPP Investment Board deal

Pozen sold its royalty and milestone rights associated with U.S. sales of migraine drug Treximet sumatriptan/naproxen to CPPIB's CPPIB Credit Investments Inc. unit for $75 million. Pozen is eligible for milestones and royalties from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.), which has U.S. marketing rights from Pozen under a 2003 deal (see BioCentury, June 16, 2003). ...